Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6986744 | 0.88 | ALDH1A1 (0.61) | CYP1A2CYP3A4CYP2C19ALDH1A1MAPT | |
| SCHEMBL25734367 | 0.87 | ALDH1A1 (0.49) | CYP1A2CYP3A4CYP2C19ALDH1A1MAPT | |
| SCHEMBL2593397 | 0.87 | ALDH1A1 (0.60) | CYP1A2CYP3A4CYP2C19ALDH1A1MAPT | |
| SCHEMBL5673785 | 0.87 | ALDH1A1 (0.60) | CYP1A2CYP3A4CYP2C19ALDH1A1MAPT | |
| SCHEMBL221788 | 0.86 | MTNR1A (0.53) | CYP1A2CYP3A4CYP2C19ALDH1A1MAPT | |
| SCHEMBL5700816 | 0.86 | ALDH1A1 (0.43) | CYP1A2CYP3A4CYP2C19ALDH1A1MAPT | |
| SCHEMBL3662358 | 0.86 | PDGFRB (0.43) | CYP1A2CYP3A4CYP2C19ALDH1A1MAPT | |
| SCHEMBL6588549 | 0.85 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C19ALDH1A1MAPT | |
| SCHEMBL5065594 | 0.85 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C19ALDH1A1MAPT | |
| SCHEMBL4992802 | 0.84 | ALDH1A1 (0.52) | CYP1A2CYP3A4CYP2C19ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4387603-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118103038-A | 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2021018118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | WO | disclosed |
| US-8716287-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| US-8642657-B2 | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| EP-2569290-A2 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2011141716-A2 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | CYP1A2 83/4885CYP3A4 228/4885CYP2C19 110/4885 |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | CYP1A2 83/4885CYP3A4 228/4885CYP2C19 110/4885 |
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | CSNK1A1, FRK, CSNK1E | CYP1A2 1029/4885CYP3A4 460/4885CYP2C19 1218/4885 |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | HSD17B1, HSD17B13, HSD17B3 | CYP1A2 83/4885CYP3A4 228/4885CYP2C19 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.